Abdominal MRI using a negative contrast agent.
A dose of 0.5 g of a negative oral contrast agent for labelling the bowel, was given to 40 patients in a clinical trial. Oral magnetic particles (OMP) consist of crystals of iron oxide with superparamagnetic properties, and are administered in 800 ml of a viscous suspension in order to obtain a uniform distribution. The aim of the study was to identify any adverse effects up to 1 week following ingestion, as well as the contrast distribution and effect, together with the induction of artifacts. A comparison of diagnostic value of the pre and postcontrast ingestion series was also performed. Vomiting followed ingestion in a single patient already nauseated and was the only adverse effect. Good contrast distribution and effect with no artifacts were present. The diagnostic information was greatly improved after OMP ingestion, and the diagnosis would not have been possible without the use of the contrast agent in 41% of the examinations.
Bach-Gansmo
T
T
Nycomed, Oslo, Norway.
Dupas
B
B
Gayet-Delacroix
M
M
Lambrechts
M
M
D000008:Abdominal Neoplasms / Q000175:diagnosis* / Q000473:pathology; D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D004064:Digestive System / Q000473:pathology; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron / Q000009:adverse effects; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000009:adverse effects; D014783:Viscosity; D014839:Vomiting / Q000139:chemically induced
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide